RGEN
Neutral signalScored 2026-10-20 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Repligen Corporation
- Nom
- Repligen Corporation
- Secteur
- Healthcare
- Industrie
- Medical - Instruments & Supplies
- Bourse
- NASDAQ
- Capitalisation
- $11.3B
- Employés
- 2,000
- PDG
- Olivier Loeillot
- Site web
- https://www.repligen.com
- Marché
- AAVTRBIOBLFSMRVIQGEN
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 18 538 titres (~3 332 547,75 $ US)
- Insiders
- Loeillot Olivier
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$4,118,226
Avg sell (VWAP, 90d window) $181.97 vs last close $178.71 (-1.8%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$4,118,226 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-05
- Liquidity
- Liquid $235,145,698/day · 20d vol
- Last synced
-
2026-10-22 21:11:03
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-05 | Loeillot Olivier | Sell · S · 10b5-1 | 4,202 | $190.00 | $798,380 | Form 4 |
| 2026-09-24 | Loeillot Olivier | Sell · S · 10b5-1 | 4,542 | $190.00 | $862,980 | Form 4 |
| 2026-09-21 | Loeillot Olivier | Sell · S · 10b5-1 | 5,426 | $180.00 | $976,680 | Form 4 |
| 2026-09-04 | Loeillot Olivier | Sell · S · 10b5-1 | 3,035 | $165.90 | $503,506 | Form 4 |
| 2026-08-20 | Loeillot Olivier | Sell · S · 10b5-1 | 5,426 | $180.00 | $976,680 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-10-31 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-10-30 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-10-30 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-07-22 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-06-17 | Lisa C. McClain | Sale (Partial) | $1,001 - $15,000 |
| 2025-06-11 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-04-07 | Jefferson Shreve | Sale (Full) | $15,001 - $50,000 |
| 2022-04-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-01-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-01-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-20 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
Repligen's completed acquisition of BioLife Solutions represents a meaningful structural growth catalyst, supported by a fortress-like liquidity position (current ratio 8.37) that de-risks integration execution.
The first sentence of the analysis written for RGEN on 2026-10-20 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $4.1M) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $4.1M) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Congress Supports a bullish reading. 3 purchase disclosures year to date
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Supports a bullish reading. Current ratio 8.37 · operating margin 8.1%
Suggested stop 161.20, nearest stored support minus 0.5 ATR(9.8% under the last close). Reward/risk to the next stored resistance is 0.57. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-15 Repligen Corporation $RGEN Stock Sold by Krilogy Financial LLC Krilogy Financial LLC lowered its position in shares of Repligen Corporation (NASDAQ: RGEN) by 31.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,066 shares of the biotechnology company''s stock after selling 7,033 shares during the quarter. Krilogy Financial LLC''s holdings in
- 2026-10-14 Repligen: A Buy As Its Growth Engine Gears Up Repligen demonstrates 13% organic growth despite Filtration headwinds, with strong momentum in the Proteins and Process Analytics segments. Filtration''s drag is temporary, with mid-single-digit growth expected in 2026 and order activity fueling a robust 2027 backlog. The BioLife acquisition adds high-margin, sticky cell therapy consumables, with anticipated synergies and accretive EPS contributions post-closing.
- 2026-10-13 Repligen to Report Third Quarter 2026 Financial Results WALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that the Company will report its third quarter 2026 financial results on Tuesday, October 27, 2026.
- 2026-10-06 Repligen Corp (RGEN) Shares Fall 7.7% -- What GF Score of 85 Tells Investors On October 06, 2026, Repligen Corp (RGEN) shares experienced a notable decline of 7.7%, bringing the current price to $174.86. This movement comes amid a 52-wee
- 2026-10-06 Repligen Completes Acquisition of BioLife Solutions WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company focused on bioprocessing technology leadership, today announced it has completed the previously announced acquisition of BioLife Solutions, Inc. (NASDAQ: BLFS, “BioLife”), a leading developer and supplier of cell processing tools and services for the cell and gene therapy market. “We are excited to welcome BioLife team members to Repligen,” said Olivier Loeillot, President and Chief Executive Officer of Repligen. “BioLife''s highly-differentiated portfolio of products expands our presence in the rapidly growing cell therapy market, adding a deeply embedded, high-margin consumables business with attractive recurring revenue. Together, we are better positioned to support customers across critical stages of the cell therapy workflow and help advance the development and commercialization of next-generation therapies. Over the past several months, our teams have worked closely together to develop a thoughtful integration plan, and we are even more excited about the strategic rationale of bringing our organizations together and the value we will create for patients, customers, and shareholders.” BioLife''s products are deeply embedded in the cell therapy workflow and highly complementary to Repligen''s existing offering in this market. BioLife''s differentiated biopreservation media portfolio, led by CryoStor®, supports 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based therapy trials. As a combined commercial team, BioLife will benefit from Repligen''s broader global reach, including Asia Pacific, while Repligen will benefit from BioLife''s trusted customer relationships. In connection with the transaction, BioLife stockholders received $11.25 per share in cash and 0.1442 shares of Repligen common stock, with cash in lieu of any fractional shares of Repligen common stock. Repligen intends to provide additional detail regarding the transaction''s expected impact on Repligen''s 2026 financial outlook in the upcoming third quarter 2026 earnings call. Advisors Perella Weinberg Partners LP and Goldman Sachs & Co. LLC served as financial advisors and Goodwin Procter LLP served as legal counsel to Repligen. Centerview Partners, LLC served as financial advisor and K&L Gates LLP served as legal counsel to BioLife. About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve, primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn . Forward-Looking Statements This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements regarding the expected benefits of the transaction and Repligen''s ability to recognize such benefits; the anticipated financial impact of the transaction on Repligen; expectations for Repligen''s performance following the transaction; and beliefs and expectations about the cell therapy industry, including its growth, and BioLife''s position as a highly-differentiated cell processing tool leader. Words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and variations of such words and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law. Repligen Contact: Jacob JohnsonVP, Investor [email protected]
- 2026-10-05 Repligen Corp (RGEN) Stock Up 4.3% but GF Value Says Overvalued -- GF Score: 85/100 On October 05, 2026, Repligen Corp (RGEN) shares rose 4.3%, bringing the current price to $189.50. The stock has experienced a 52-week range from a low of $100.
- 2026-10-05 BioLife Solutions Shareholders Approve Repligen Merger Agreement BioLife Solutions NASDAQ: BLFS stockholders approved the company''s merger agreement with Repligen Corporation at a special meeting held virtually on Oct. 5, 2026, clearing a key shareholder-vote requirement for the proposed transaction.
- 2026-09-25 Repligen (NASDAQ:RGEN) Hits New 52-Week High – Still a Buy? Repligen Corporation (NASDAQ: RGEN - Get Free Report) reached a new 52-week high on Wednesday. The stock traded as high as $188.95 and last traded at $186.9330, with a volume of 25119 shares traded. The stock had previously closed at $186.75. Wall Street Analysts Forecast Growth A number of brokerages have issued reports on RGEN. HSBC
- 2026-09-19 Tidal Investments LLC Raises Holdings in Repligen Corporation $RGEN Tidal Investments LLC increased its stake in shares of Repligen Corporation (NASDAQ: RGEN) by 75.2% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,863 shares of the biotechnology company''s stock after acquiring an additional 3,803 shares during
- 2026-09-10 BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioLife Solutions, Inc. (NasdaqCM: BLFS) to Repligen Corporation (NasdaqGS: RGEN). Under the terms of the proposed transaction, shareholders of BioLife will receive $11.25 in cash and 0.1442 shares of Repligen common stock for each share of BioLife that they own. KSF is seeking to determine whether t.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 47.1% | 43.3% | 44.0% | 56.9% | 58.3% | |
| Ebit Margin | 11.6% | -1.0% | 9.4% | 27.5% | 24.6% | |
| Ebitda Margin | 24.7% | 12.7% | 23.0% | 34.6% | 30.3% | |
| Operating Profit Margin | 8.1% | -5.5% | 7.5% | 28.0% | 24.9% | |
| Pretax Profit Margin | 8.5% | -4.3% | 9.0% | 27.3% | 22.9% | |
| Continuous Operations Profit Margin | 6.6% | -4.0% | 5.6% | 23.2% | 19.1% | |
| Net Profit Margin | 6.6% | -4.0% | 5.6% | 23.2% | 19.1% | |
| Bottom Line Profit Margin | 6.6% | -4.0% | 5.6% | 23.2% | 19.1% | |
| Current Ratio | 8.374 | 8.408 | 6.738 | 2.469 | 2.483 | |
| Quick Ratio | 7.119 | 7.281 | 5.511 | 1.880 | 1.991 | |
| Solvency Ratio | 0.173 | 0.071 | 0.140 | 0.391 | 0.274 | |
| Cash Ratio | 4.167 | 5.973 | 4.555 | 1.295 | 1.609 | |
| Price To Earnings Ratio | 188.345 | -312.913 | 280.938 | 50.540 | 113.665 | |
| Price To Earnings Growth Ratio | -0.651 | 1.821 | -3.473 | 1.154 | 1.089 | |
| Forward Price To Earnings Growth Ratio | -0.651 | 1.821 | -3.473 | 1.154 | 1.089 | |
| Price To Earnings Diluted Ratio | 190.535 | -312.913 | 285.397 | 52.256 | 118.232 | |
| Price To Earnings Diluted Growth Ratio | -0.664 | 1.809 | -3.543 | 1.171 | 1.161 | |
| Price To Book Ratio | 4.375 | 4.081 | 5.099 | 4.914 | 8.325 | |
| Price To Sales Ratio | 12.481 | 12.691 | 15.843 | 11.715 | 21.729 | |
| Price To Free Cash Flow Ratio | 98.133 | 56.507 | 133.704 | 242.402 | 280.590 | |
| Price To Operating Cash Flow Ratio | 78.477 | 45.906 | 87.944 | 54.566 | 122.422 | |
| Debt To Assets Ratio | 0.234 | 0.243 | 0.251 | 0.167 | 0.155 | |
| Debt To Equity Ratio | 0.328 | 0.348 | 0.362 | 0.221 | 0.209 | |
| Debt To Capital Ratio | 0.247 | 0.258 | 0.266 | 0.181 | 0.173 | |
| Long Term Debt To Capital Ratio | 0.205 | 0.210 | 0.206 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.401 | 1.434 | 1.441 | 1.325 | 1.348 | |
| Working Capital Turnover Ratio | 0.761 | 0.673 | 0.821 | 1.394 | 1.177 | |
| Operating Cash Flow Ratio | 0.864 | 1.383 | 0.691 | 0.426 | 0.317 | |
| Operating Cash Flow Sales Ratio | 0.159 | 0.276 | 0.180 | 0.215 | 0.177 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.800 | 0.812 | 0.658 | 0.225 | 0.436 | |
| Debt Service Coverage Ratio | 3.779 | 3.623 | 1.563 | 0.849 | 0.664 | |
| Interest Coverage Ratio | 2.571 | -1.556 | 4.758 | 75.469 | 13.155 | |
| Short Term Operating Cash Flow Coverage Ratio | 5.446 | 0.000 | 1.640 | 0.605 | 0.466 | |
| Operating Cash Flow Coverage Ratio | 0.170 | 0.256 | 0.160 | 0.407 | 0.325 | |
| Capital Expenditure Coverage Ratio | 4.992 | 5.330 | 2.922 | 1.290 | 1.774 | |
| Dividend Paid And Capex Coverage Ratio | 4.992 | 5.330 | 2.922 | 1.290 | 1.774 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 51.166 | 99.435 | 68.667 | 33.498 | 70.510 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 47.1% | ▲3.8% | ▼-2.8% |
| Ebit Margin | 11.6% | ▲12.6% | ▼-2.8% |
| Ebitda Margin | 24.7% | ▲12.1% | ▼-0.3% |
| Operating Profit Margin | 8.1% | ▲13.6% | ▼-4.5% |
| Pretax Profit Margin | 8.5% | ▲12.7% | ▼-4.2% |
| Continuous Operations Profit Margin | 6.6% | ▲10.6% | ▼-3.5% |
| Net Profit Margin | 6.6% | ▲10.6% | ▼-3.5% |
| Bottom Line Profit Margin | 6.6% | ▲10.6% | ▼-3.5% |
| Current Ratio | 8.374 | ▼-0.034 | ▲2.679 |
| Quick Ratio | 7.119 | ▼-0.162 | ▲2.363 |
| Solvency Ratio | 0.173 | ▲0.102 | ▼-0.037 |
| Cash Ratio | 4.167 | ▼-1.806 | ▲0.647 |
| Price To Earnings Ratio | 188.345 | ▲501.258 | ▲124.230 |
| Price To Earnings Growth Ratio | -0.651 | ▼-2.472 | ▼-0.639 |
| Forward Price To Earnings Growth Ratio | -0.651 | ▼-2.472 | ▼-0.639 |
| Price To Earnings Diluted Ratio | 190.535 | ▲503.448 | ▲123.834 |
| Price To Earnings Diluted Growth Ratio | -0.664 | ▼-2.473 | ▼-0.651 |
| Price To Book Ratio | 4.375 | ▲0.294 | ▼-0.984 |
| Price To Sales Ratio | 12.481 | ▼-0.209 | ▼-2.410 |
| Price To Free Cash Flow Ratio | 98.133 | ▲41.627 | ▼-64.134 |
| Price To Operating Cash Flow Ratio | 78.477 | ▲32.571 | ▲0.614 |
| Debt To Assets Ratio | 0.234 | ▼-0.009 | ▲0.024 |
| Debt To Equity Ratio | 0.328 | ▼-0.020 | ▲0.034 |
| Debt To Capital Ratio | 0.247 | ▼-0.011 | ▲0.022 |
| Long Term Debt To Capital Ratio | 0.205 | ▼-0.006 | ▲0.081 |
| Financial Leverage Ratio | 1.401 | ▼-0.034 | ▲0.011 |
| Working Capital Turnover Ratio | 0.761 | ▲0.088 | ▼-0.204 |
| Operating Cash Flow Ratio | 0.865 | ▼-0.519 | ▲0.128 |
| Operating Cash Flow Sales Ratio | 0.159 | ▼-0.117 | ▼-0.043 |
| Free Cash Flow Operating Cash Flow Ratio | 0.800 | ▼-0.013 | ▲0.213 |
| Debt Service Coverage Ratio | 3.779 | ▲0.156 | ▲1.683 |
| Interest Coverage Ratio | 2.571 | ▲4.127 | ▼-16.308 |
| Short Term Operating Cash Flow Coverage Ratio | 5.446 | ▲5.446 | ▲3.815 |
| Operating Cash Flow Coverage Ratio | 0.170 | ▼-0.085 | ▼-0.093 |
| Capital Expenditure Coverage Ratio | 4.992 | ▼-0.338 | ▲1.731 |
| Dividend Paid And Capex Coverage Ratio | 4.992 | ▼-0.338 | ▲1.731 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 51.166 | ▼-48.269 | ▼-13.489 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $9.21B | $8.05B | $10.02B | $9.39B | $14.57B | |
| Enterprise value | $9.34B | $7.98B | $9.98B | $9.29B | $14.33B | |
| EV / Sales | 12.65x | 12.58x | 15.78x | 11.59x | 21.38x | |
| EV / Op. cash flow | 79.53x | 45.50x | 87.60x | 53.98x | 120.42x | |
| EV / Free cash flow | 99.45x | 56.01x | 133.18x | 239.81x | 276.01x | |
| EV / EBITDA | 51.17x | 99.44x | 68.67x | 33.50x | 70.51x | |
| Net debt / EBITDA | 0.68x | -0.89x | -0.27x | -0.36x | -1.17x | |
| Current ratio | 8.37x | 8.41x | 6.74x | 2.47x | 2.48x | |
| Income quality | 2.40x | -6.87x | 2.74x | 0.93x | 0.93x | |
| Graham number | $27 | — | $23 | $51 | $41 | |
| Graham net-net | $2 | $1 | $1 | $4 | $3 | |
| Tax burden | 78.4% | 94.4% | 62.8% | 84.9% | 83.6% | |
| Interest burden | 72.9% | 428.9% | 95.8% | 99.5% | 93.2% | |
| Working capital | $1.00B | $939.3M | $946.4M | $593.9M | $556.4M | |
| Invested capital | $2.81B | $2.70B | $2.66B | $2.13B | $1.98B | |
| Return on assets | 1.7% | -0.9% | 1.3% | 7.3% | 5.4% | |
| Operating ROA | 2.1% | -1.2% | 1.8% | 9.2% | 7.8% | |
| Return on tangible assets | 3.4% | -1.8% | 2.5% | 14.1% | 11.1% | |
| Return on equity | 2.3% | -1.3% | 1.8% | 9.7% | 7.3% | |
| Return on invested capital | 1.6% | -1.2% | 1.1% | 7.9% | 6.2% | |
| Return on capital employed | 2.1% | -1.3% | 1.8% | 10.6% | 8.4% | |
| Earnings yield | 0.5% | -0.3% | 0.4% | 2.0% | 0.9% | |
| Free cash flow yield | 1.0% | 1.8% | 0.7% | 0.4% | 0.4% | |
| Capex / Op. cash flow | 20.0% | 18.8% | 34.2% | 77.5% | 56.4% | |
| Capex / Depreciation | 24.3% | 38.0% | 45.3% | 233.9% | 174.5% | |
| Capex / Sales | 3.2% | 5.2% | 6.2% | 16.6% | 10.0% | |
| SG&A / Sales | 39.4% | 41.5% | 34.6% | 26.9% | 27.4% | |
| R&D / Sales | 7.3% | 6.8% | 6.8% | 5.5% | 5.1% | |
| Stock comp / Sales | 4.4% | 7.6% | 4.0% | 3.4% | 4.1% | |
| Intangibles / Total assets | 50.9% | 50.5% | 49.2% | 48.0% | 50.8% | |
| Days sales outstanding | 78d | 77d | 72d | 53d | 64d | |
| Days payables outstanding | 28d | 33d | 20d | 29d | 47d | |
| Operating cycle | 238d | 222d | 280d | 304d | 305d | |
| Cash conversion cycle | 210d | 190d | 260d | 275d | 258d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years